Guardant Health Investor Presentation

LUNAR Assay Performance Hybrid genomics and epigenomics approach can improve sensitivity to early stage cancers Internal Guardant Health data Genomic Alterations 100 10 T 0.1 0.01 0.001 0.0001 0.00001 0.000001 Normal Late-stage Early-stage 0.000001 0.00001 0.0001 0.001 TTTTT 0.01 0.1 1 Epigenomic Signatures . • Assay reportable range down to 0.01% for genomic alterations High quantitative correlation between genomic and epigenomic signal components Epigenomic component detects many samples that were negative with genomics-only component 22 GUARDANT™

View entire presentation